Delving into the Latest Updates on Accro Bioscience (Suzhou) Co., Ltd. with Synapse

Overview

Tags

Immune System Diseases

Skin and Musculoskeletal Diseases

Other Diseases

Small molecule drug

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	5
Hemic and Lymphatic Diseases	2
Neoplasms	2
Nervous System Diseases	1
Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	5
Chemical drugs	1

Top 5 Target	Count

RIPK1(Receptor-interacting serine/threonine-protein kinase 1)	1
RIPK2(Serine/threonine-protein kinase RIPK2)	1
JAK1 x TYK2	1

主要目的：评价健康受试者多次口服AC-101片后的安全性和耐受性。次要目的：评价健康受试者多次口服AC-101片后的药代动力学特征。评价食物对健康受试者口服AC-101片药代动力学特征的影响。其他目的：评价多次给药后血浆中AC-101的代谢产物。

[Translation]

Primary objective: To evaluate the safety and tolerability of AC-101 tablets after multiple oral administration in healthy subjects. Secondary objective: To evaluate the pharmacokinetic characteristics of AC-101 tablets after multiple oral administration in healthy subjects. To evaluate the effect of food on the pharmacokinetic characteristics of AC-101 tablets after oral administration in healthy subjects. Other objectives: To evaluate the metabolites of AC-101 in plasma after multiple administration.

Start Date16 Sep 2024

Sponsor / Collaborator

Accro Bioscience (Suzhou) Co., Ltd.Startup

CTR20233988

/ RecruitingPhase 1

评价AC-003胶囊联合糖皮质激素治疗糖皮质激素耐药的急性移植物抗宿主病（aGVHD）的安全性、耐受性、初步疗效及药代动力学特征的Ib期临床试验

[Translation] A Phase Ib clinical trial to evaluate the safety, tolerability, preliminary efficacy and pharmacokinetic characteristics of AC-003 capsule combined with glucocorticoids in the treatment of glucocorticoid-resistant acute graft-versus-host disease (aGVHD)

主要目的：评价AC-003胶囊治疗aGVHD的安全性和耐受性；次要目的：观察AC-003胶囊治疗aGVHD的初步疗效；评价AC-003胶囊在aGVHD受试者中的药代动力学特征；其他目的：研究AC-003给药后的生物标志物/药效标志物。

[Translation]

Primary purpose: To evaluate the safety and tolerability of AC-003 capsules in the treatment of aGVHD; Secondary purpose: To observe the preliminary efficacy of AC-003 capsules in the treatment of aGVHD; To evaluate the pharmacokinetic characteristics of AC-003 capsules in subjects with aGVHD; Other purposes: To study biomarkers/pharmacodynamic markers after AC-003 administration.

Start Date22 Jul 2024

Sponsor / Collaborator

Accro Bioscience (Suzhou) Co., Ltd.Startup

100 Clinical Results associated with Accro Bioscience (Suzhou) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Accro Bioscience (Suzhou) Co., Ltd.

Login to view more data

100 Deals associated with Accro Bioscience (Suzhou) Co., Ltd.

Login to view more data

100 Translational Medicine associated with Accro Bioscience (Suzhou) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 31 Mar 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

1

2

IND Application

Phase 1

2

1

Phase 2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

AC-003 ( RIPK1 )	Acute Graft Versus Host Disease More	Phase 1
AC-101 ( RIPK2 )	Colitis, Ulcerative More	Phase 1
AC-201 ( JAK1 x TYK2 )	Uveitis More	IND Approval
AC-203 (Accro Bioscience)	Anemia, Aplastic More	IND Application
AC-301(Accro Bioscience)	Diffuse Large B-Cell Lymphoma More	IND Application